Zhang Yun, Wang Xing, Zhang He, Tang Hongmei, Hu Hang, Wang Songping, Wong Vincent Kam Wai, Li Yuying, Deng Jun
Inflammation and Allergic Diseases Research Unit, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Front Pharmacol. 2021 Jul 23;12:710679. doi: 10.3389/fphar.2021.710679. eCollection 2021.
Asthma has become a global health issue, suffering more than 300 million people in the world, which is a heterogeneous disease, usually characterized by chronic airway inflammation and airway hyperreactivity. Combination of inhaled corticosteroids (ICS) and long acting β-agonists (LABA) can relieve asthma symptoms and reduce the frequency of exacerbations, especially for patients with refractory asthma, but there are limited treatment options for people who do not gain control on combination ICS/LABA. The increase in ICS dose generally provides little additional benefit, and there is an increased risk of side effects. Therefore, therapeutic interventions integrating the use of different agents that focus on different targets are needed to overcome this set of diseases. Some findings suggest autophagy is closely correlated with the severity of asthma through eosinophilic inflammation, and its modulation may provide novel therapeutic approaches for severe allergic asthma. The chinese herbal medicine (CHM) have been demonstrated clinically as potent therapeutic interventions for asthma. Moreover some reports have found that the bioactive components isolated from CHM could modulate autophagy, and exhibit potent Anti-inflammatory activity. These findings have implied the potential for CHMs in asthma or allergic inflammation therapy via the modulation of autophagy. In this review, we discuss the basic pathomechanisms underpinning asthma, and the potential role of CHMs in treating asthma with modulating autophagy.
哮喘已成为一个全球性的健康问题,全球有超过3亿人受其困扰。哮喘是一种异质性疾病,通常以慢性气道炎症和气道高反应性为特征。吸入性糖皮质激素(ICS)和长效β受体激动剂(LABA)联合使用可缓解哮喘症状并减少急性加重的频率,特别是对于难治性哮喘患者,但对于那些在ICS/LABA联合治疗下仍无法控制病情的人来说,治疗选择有限。增加ICS剂量通常不会带来更多益处,而且副作用风险会增加。因此,需要整合使用针对不同靶点的不同药物的治疗干预措施来攻克这类疾病。一些研究结果表明,自噬通过嗜酸性粒细胞炎症与哮喘的严重程度密切相关,对其进行调节可能为重度过敏性哮喘提供新的治疗方法。中药已在临床上被证明是治疗哮喘的有效干预措施。此外,一些报告发现,从中药中分离出的生物活性成分可以调节自噬,并表现出强大的抗炎活性。这些发现暗示了中药通过调节自噬在哮喘或过敏性炎症治疗中的潜力。在这篇综述中,我们讨论了哮喘的基本发病机制,以及中药在通过调节自噬治疗哮喘中的潜在作用。